Prediction value of neutrophil and eosinophil count at risk of COPD exacerbation

Ann Med. 2023;55(2):2285924. doi: 10.1080/07853890.2023.2285924. Epub 2023 Dec 8.

Abstract

Introduction: Predicting acute exacerbations (AEs) in chronic obstructive pulmonary disease (COPD) is crucial. This study aimed to identify blood biomarkers for predicting COPD exacerbations by inflammatory phenotypes.

Materials and methods: We analyzed blood cell counts and clinical outcomes in 340 COPD patients aged 20-90 years. Patients were categorized into eosinophilic inflammation (EOCOPD) and non-eosinophilic inflammation (N-EOCOPD) groups. Blood cell counts, eosinophil-to-lymphocyte ratio (ELR), neutrophil-to-lymphocyte ratio (NLR) and neutrophil-to-eosinophil ratio (NER) were calculated. Linear and logistic regression models assessed relationships between health outcomes and blood cell counts.

Results: EOCOPD patients had distinct characteristics compared to N-EOCOPD patients. Increased neutrophil % and decreased lymphocyte % were associated with reduced pulmonary function, worse quality of life and more exacerbations, but they did not show statistical significance after adjusting by age, sex, BMI, smoking status, FEV1% and patient's medication. Subgroup analysis revealed a 1.372-fold increase in the OR of AE for every 1 unit increase in NLR in EOCOPD patients (p < .05). In N-EOCOPD patients, every 1% increase in blood eosinophil decreased the risk of exacerbation by 59.6%.

Conclusions: Our study indicates that distinct white blood cell profiles in COPD patients, with or without eosinophilic inflammation, can help assess the risk of AE in clinical settings.

Keywords: Acute exacerbation; COPD; eosinophil; inflammation; neutrophil.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disease Progression
  • Eosinophilia*
  • Eosinophils
  • Humans
  • Inflammation
  • Leukocyte Count
  • Neutrophils
  • Pulmonary Disease, Chronic Obstructive*
  • Quality of Life
  • Retrospective Studies

Grants and funding

This study was funded by the National of Science and Technology Council of Taiwan [112-2314-B-038-013 and 112-2628-B-038-010-MY3] and Taipei Medical University [TMU112-AE1-B05].